DRW Securities LLC acquired a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,800 shares of the biopharmaceutical company’s stock, valued at approximately $219,000.

A number of other institutional investors have also recently made changes to their positions in ALXN. Neuberger Berman Group LLC raised its stake in Alexion Pharmaceuticals by 29.9% in the 1st quarter. Neuberger Berman Group LLC now owns 6,189 shares of the biopharmaceutical company’s stock valued at $750,000 after acquiring an additional 1,423 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in Alexion Pharmaceuticals by 1.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 8,770 shares of the biopharmaceutical company’s stock valued at $1,063,000 after acquiring an additional 100 shares during the period. Credit Agricole S A raised its stake in Alexion Pharmaceuticals by 10.4% in the 1st quarter. Credit Agricole S A now owns 69,166 shares of the biopharmaceutical company’s stock valued at $8,384,000 after acquiring an additional 6,524 shares during the period. Teachers Advisors LLC raised its stake in Alexion Pharmaceuticals by 3.0% in the 1st quarter. Teachers Advisors LLC now owns 422,267 shares of the biopharmaceutical company’s stock valued at $51,196,000 after acquiring an additional 12,179 shares during the period. Finally, Bridgewater Associates LP bought a new stake in Alexion Pharmaceuticals in the 1st quarter valued at about $1,621,000. Institutional investors and hedge funds own 94.25% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “DRW Securities LLC Takes Position in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/drw-securities-llc-takes-position-in-alexion-pharmaceuticals-inc-alxn/1618106.html.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 1.73% on Friday, hitting $141.30. The stock had a trading volume of 1,104,777 shares. The firm has a 50-day moving average price of $141.26 and a 200-day moving average price of $126.29. The stock has a market capitalization of $31.54 billion, a P/E ratio of 61.27 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm’s quarterly revenue was up 21.1% on a year-over-year basis. During the same quarter last year, the company earned $1.13 EPS. Equities analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the transaction, the executive vice president now owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. Insiders have sold a total of 17,190 shares of company stock worth $2,433,669 in the last three months. 4.35% of the stock is owned by corporate insiders.

A number of brokerages recently issued reports on ALXN. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Leerink Swann restated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price objective on the stock. Deutsche Bank AG restated a “buy” rating and issued a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $154.56.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.